Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
XENE 
Xenon Pharmaceuticals Inc (XENE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: XENE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $55.03
1 Year Target Price $55.03
| 14 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.45% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.25B USD | Price to earnings Ratio - | 1Y Target Price 55.03 |
Price to earnings Ratio - | 1Y Target Price 55.03 | ||
Volume (30-day avg) 19 | Beta 1.14 | 52 Weeks Range 26.74 - 46.00 | Updated Date 10/17/2025 |
52 Weeks Range 26.74 - 46.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4241.6% |
Management Effectiveness
Return on Assets (TTM) -25.52% | Return on Equity (TTM) -37.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2543717320 | Price to Sales(TTM) 433.54 |
Enterprise Value 2543717320 | Price to Sales(TTM) 433.54 | ||
Enterprise Value to Revenue 339.16 | Enterprise Value to EBITDA -11.81 | Shares Outstanding 77105799 | Shares Floating 71595819 |
Shares Outstanding 77105799 | Shares Floating 71595819 | ||
Percent Insiders 0.14 | Percent Institutions 110.69 |
Upturn AI SWOT
Xenon Pharmaceuticals Inc
Company Overview
History and Background
Xenon Pharmaceuticals Inc. is a biopharmaceutical company founded in 1996. It focuses on developing therapeutics for neurological disorders. The company has evolved from gene discovery to clinical-stage drug development.
Core Business Areas
- Neurology: Developing therapies for neurological disorders such as epilepsy, pain, and other CNS conditions. Focus on small molecule therapeutics.
Leadership and Structure
Dr. Ian Mortimer is the CEO. The company has a typical biopharmaceutical organizational structure with research, development, clinical, and commercial departments.
Top Products and Market Share
Key Offerings
- XEN1101 (active ingredient ezogabine): A Kv7 potassium channel opener being developed for the treatment of epilepsy. It's currently in phase 3 clinical trials. Competitors include existing anti-epileptic drugs from companies like UCB (UCBJF), Eisai (ESALY) and generic manufacturers.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and driven by innovation. It involves significant R&D investment and regulatory hurdles.
Positioning
Xenon is positioned as a neurology-focused drug developer specializing in small molecule therapies. Its competitive advantage lies in its Kv7 channel modulation expertise.
Total Addressable Market (TAM)
The global epilepsy therapeutics market is expected to reach $12.3 billion by 2028. Xenon is positioning itself to capture a share of this market with XEN1101.
Upturn SWOT Analysis
Strengths
- Strong expertise in Kv7 channel modulation
- Promising lead candidate (XEN1101) in Phase 3 trials
- Experienced management team
- Proprietary drug discovery platform
Weaknesses
- Reliance on a limited number of product candidates
- High cash burn rate typical of biopharmaceutical companies
- Dependence on successful clinical trial outcomes
- Currently has limited revenue streams
Opportunities
- Potential regulatory approval and commercialization of XEN1101
- Expansion of pipeline through internal discovery and partnerships
- Acquisition by a larger pharmaceutical company
- Expansion into new neurological indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other pharmaceutical companies
- Patent challenges
- Generic erosion of approved products
Competitors and Market Share
Key Competitors
- UCBJF
- ESALY
- GWPH
Competitive Landscape
Xenon competes with both established pharmaceutical companies and other biotech firms developing neurological therapies. Xenonu2019s advantage is in their targeted small molecule approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by pipeline advancement and clinical trial progress. No sales growth until a product is approved.
Future Projections: Future projections depend on the successful commercialization of XEN1101 and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing XEN1101 through Phase 3 clinical trials and expanding the pipeline through internal discovery.
Summary
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising lead compound targeting epilepsy. While its success is contingent on positive clinical trial outcomes and regulatory approvals, its expertise in Kv7 channel modulation provides a competitive edge. The company needs to manage its cash burn carefully and mitigate risks associated with clinical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Data accuracy is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Burnaby, BC, Canada | ||
IPO Launch date 2014-11-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.xenon-pharma.com |
Full time employees 316 | Website https://www.xenon-pharma.com | ||
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.